Fecal galectin-1 as a potential marker for colorectal cancer and disease severity

Jovanovic, Milan; Gajovic, Nevena; Zdravković, Nataša; Jovanović, Marina; Jurišević, Milena; Vojvodić, Danilo; Mirković, Darko; Milev, Bosko; Maric, Veljko; Arsenijević, Nebojša

doi:10.2298/vsp171201007j

Cited by 5 publications

(6 citation statements)

References 35 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-inflammatory role of Gal-1 is reflected in the fact that it converted macrophages from their proinflammatory to anti-inflammatory profile thus terminating the inflammation 29 . Our previous work revealed predomination of Gal-1 over proinflammatory cytokines in patients with colorectal cancer, suggested on the immunomodulatory function of Gal-1 in the restriction of inflammation 30 . Our results confirmed the results of previous studies that systemic levels of proinflammatory cytokines IL-1 and IL-6 are rising during the progression of COVID-19 suggesting on ongoing development of inflammation 31 .…”

Section: Discussionmentioning

confidence: 90%

Galectin-1 as the new player in staging and prognosis of COVID-19

Marković

Gajovic

Jurišević

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

A new virus from the group of coronaviruses was identified as the cause of atypical pneumonia and called Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and disease called Corona Virus Disease (COVID-19). During the cytokine storm, the main cause of the death, proinflammatory cytokines are released which stimulate further tissue destruction. Galectin-1 (Gal-1) is a pleiotropic cytokine involved in many immune and inflammatory processes and its role in COVID-19 is still unknown. The aim of this study was to determine systemic values of Gal-1 and correlations between Gal-1 and proinflammatory cytokines and clinical parameters during COVID-19 progression. This is observational and cross-sectional study. 210 COVID-19 patients were included and divided into mild, severe or critical group according to COVID-19 severity. Serum levels of IL-1β, IL-6, IL-10, IL-23, IL-33 and Gal-1 were measured using sensitive enzyme-linked immunosorbent assay (ELISA) kits. Systemic levels of IL-1β, IL-6, IL-10, IL-23, IL-33 and Gal-1 were significantly higher in stage III of COVID-19 patients compared to stage I and II. There were no significant differences in the ratio between Gal-1 and IL-10 with proinflammatory cytokines. Positive correlation was detected between Gal-1 and IL-1β, IL6, IL-10, IL-23 and IL-33. Gal-1 positively correlated with chest radiographic finding, dry cough and headache and negatively correlated with normal breathing sound. Linear regression model and ROC curve analysis point on Gal-1 as significant predictor for COVID-19 severity. Presented results implicate on Gal-1 and IL-10 dependent immunomodulation. The precise mechanism of Gal-1 effect in COVID-19 and its potential as a stage marker of disease severity is still to be clarified.

show abstract

Section: Discussionmentioning

confidence: 90%

Galectin-1 as the new player in staging and prognosis of COVID-19

Marković

Gajovic

Jurišević

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our previous study has also shown importance of Galectin-1 in the pathology of CRC. We noticed fecal Gal-1 in feces samples of patients with more advanced form of CRC [11] . Moreover, Gal-1 positively correlates tumor markers, such as AFP and CA 19-9 and with tumor histological differentiation stage [11] .…”

Section: Discussionmentioning

confidence: 74%

“…We noticed fecal Gal-1 in feces samples of patients with more advanced form of CRC (11). Moreover, Gal-1 positively correlates tumor markers, such as AFP and CA 19-9 and with tumor histological differentiation stage (11). According to available information, this is the first research, which investigates connection between systemic Gal-1 and anemia in CRC patients.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Anemia of inflammation in patients with colorectal cancer: Correlation with interleukin-1, interleukin-33 and galectin-1

Jocić¹

2022

J Med Biochemistry

Self Cite

View full text Add to dashboard Cite

Purpose: Patients with colorectal cancer (CRC) have anemia often present as a consequence of chronic bleeding from tumor. The exact role of lL-33, Galectin-l and IL-l in the pathological genesis of anemia in colorectal cancer patients has not been elucidated yet. The main goal of this research was to analyze Gal-l, IL-l and lL-33 systemic values in anemic and non-anemic CRC patients. Methods: Concentrations of IL-33, Galectin-1 and IL-1 have been studied in blood samples of 55 CRC patients (27 without anemia and 28 with anemia). Results: CRC patients with anemia had more severe and local advanced disease compared to CRC non-anemic patients. Anemia positively correlated with higher nuclear grade, lymph and blood vessel invasion, as well as with higher TNM stage, detectable metastatic lesions in lung and liver and peritoneal carcinomatosis. Significantly higher IL-33, Gal-1 and IL-1 concentration have been found in sera of patients with CRC and detected anemia. CRC patients mostly had microcytic anemia, while ferritin values were in normal range. Analysis revealed positive mutual correlation between serum values of galectin-1, IL-1 and IL-33 in CRC patients. Level of hemoglobin negatively correlated with serum IL-33, Gal-1 and IL-1. We have analyzed the Receiver Operating Characteristic (ROC) curves of serum IL-33, Gal-1 and IL-1 showed that these cytokines can be treated as additional markers for anemia of inflammation in CRC patients. Conclusions: Predomination of Galectin-1, IL-1 and IL-33 in anemic CRC patients implicates on their potential role in anemia genesis and further development.

show abstract

“…Galectin-1 consistently manifests heightened expression within tumor tissues, encompassing not only the neoplastic cells but also the accompanying stromal cells [16]. Notably, it plays a significant role in the carcinogenesis of colorectal tumors [57][58][59]. Such heightened levels are often indicative of a more aggressive tumor behavior, promoting the development of a metastatic phenotype [60].…”

Section: Galectin-1 In Oncology: From Tumor Progression To Therapeuti...mentioning

confidence: 99%

Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities

Bogut,

Stojanovic,

Jovanovic

et al. 2023

IJMS

View full text Add to dashboard Cite

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1’s involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies.

show abstract

Fecal galectin-1 as a potential marker for colorectal cancer and disease severity

Cited by 5 publications

References 35 publications

Galectin-1 as the new player in staging and prognosis of COVID-19

Galectin-1 as the new player in staging and prognosis of COVID-19

Anemia of inflammation in patients with colorectal cancer: Correlation with interleukin-1, interleukin-33 and galectin-1

Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities

Contact Info

Product

Resources

About